MarketPulse

PTSD

5 articles
BenzingaBenzinga··Evette Mitkov

Enveric Surges 106% on Trump's Psychedelics Push, but Downtrend Lingers

$ENVB surges 106% after Trump orders federal acceleration of psychedelic treatment approvals and commits $50M to ibogaine research, though stock remains deeply depressed technically.
ENVBbiotechregulatory approval
GlobeNewswire Inc.GlobeNewswire Inc.··Electrocore, Inc.

electroCore's Vagus Nerve Treatment Shows Promise for TBI and PTSD

electroCore publishes peer-reviewed evidence showing non-invasive vagus nerve stimulation reduces symptoms in TBI and PTSD patients.
ECORPTSDvagus nerve stimulation
GlobeNewswire Inc.GlobeNewswire Inc.··Nrx Pharmaceuticals, Inc.

NRx Pharmaceuticals to Unveil 2025 Results, Update on Breakthrough Psychiatric Drug Pipeline

NRx Pharmaceuticals to report 2025 results March 24, 2026, updating on FDA-designated ketamine and PTSD programs with significant clinical potential.
NRXPNRXPWfinancial resultsclinical-stage biopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Nrx Pharmaceuticals

NRx Subsidiary HOPE Therapeutics Expands with Florida Clinic Offering Rapid Depression, PTSD Care

NRx subsidiary HOPE Therapeutics opened a Palm Beach clinic offering same-day ketamine, TMS, and hyperbaric oxygen treatments for depression and PTSD, reporting 87% clinical response rates and 90% functional recovery with combined therapy.
NRXPNRXPWPTSDdepression treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

NRx Pharmaceuticals Names TMS Expert as Chief Medical Innovation Officer

NRx Pharmaceuticals appoints Prof. Joshua Brown, leading TMS researcher, as Chief Medical Innovation Officer to advance PTSD and depression treatments for veterans.
NRXPNRXPWclinical trialsFDA